| Balance Sheet Detail |
5. Balance Sheet Detail Property and equipment consisted of the following, in thousands:
|
|
|
|
|
|
|
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
Leasehold improvements |
$ |
7,294 |
|
|
$ |
6,919 |
|
Furniture and fixtures |
|
1,959 |
|
|
|
1,878 |
|
Laboratory and computer equipment |
|
1,943 |
|
|
|
1,958 |
|
Property and equipment, gross |
|
11,196 |
|
|
|
10,755 |
|
Less: accumulated depreciation |
|
(3,610 |
) |
|
|
(2,900 |
) |
Property and equipment, net |
$ |
7,586 |
|
|
$ |
7,855 |
|
Accrued expenses and other current liabilities consisted of the following, in thousands:
|
|
|
|
|
|
|
|
|
June 30, 2026 |
|
|
December 31, 2025 |
|
Product revenue allowances |
$ |
2,170 |
|
|
$ |
377 |
|
Accrued clinical trial research and development expenses |
|
20,086 |
|
|
|
23,276 |
|
Accrued other research and development expenses |
|
14,655 |
|
|
|
12,041 |
|
Accrued compensation and benefits |
|
14,344 |
|
|
|
22,372 |
|
Other accrued expenses |
|
3,498 |
|
|
|
3,392 |
|
Income taxes payable |
|
59 |
|
|
|
239 |
|
Total accrued expenses and other current liabilities |
$ |
54,812 |
|
|
$ |
61,697 |
|
|